Race to Slim Down: FDA Greenlights Lilly's Weight-Loss Pill 'Foundayo'

The U.S. FDA has approved Eli Lilly's weight-loss pill, Foundayo, a move that reignites competition with Novo Nordisk's oral Wegovy. Foundayo, which targets the GLP-1 hormone, offers a daily dose without dietary restrictions, promising substantial weight loss of up to 15% as demonstrated in trials.

Lilly plans to offer Foundayo for $149 per month starting April, utilizing its LillyDirect program before widespread availability. The company is seeking approval in over 40 countries and expects swift authorizations in key markets like the Gulf states. The approval was expedited under the FDA's new voucher program.

Unlike Novo's Wegovy, Foundayo can be taken any time of the day, potentially enhancing its adoption among patients and investors alike. While not expected to replace injectables, oral options like Foundayo could capture a significant market share by 2030, with demands largely influenced by affordability and side effects.